Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus
Date
2010
Authors
Van Der Laan, L.
Hudson, M.
McPherson, S.
Zondervan, P.
Thomas, R.
Kwekkeboom, J.
Lindsay, A.
Burt, A.
Kazemier, G.
Tilanus, H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Transplantation Proceedings, 2010; 42(10):4573-4577
Statement of Responsibility
L.J.W. van der Laan, M. Hudson, S. McPherson, P.E. Zondervan, R.C. Thomas, J. Kwekkeboom, A.S. Lindsay, A.D. Burt, G. Kazemier, H.W. Tilanus, M.F. Bassendine, H.J. Metselaar
Conference Name
Abstract
A 2-center retrospective analysis was performed in 60 patients undergoing liver transplantation for hepatitis C virus (HCV)–related disease (cyclosporine in 20, tacrolimus in 40). Mean (±SEM) follow-up was 23.6 ± 22.5 and 22.3 ± 13.7 months in patients receiving cyclosporine or tacrolimus, respectively. Clinically indicated biopsies were performed in 15/20 cyclosporine patients (75%) and 22/40 tacrolimus patients (55%; P = .17). The Ishak fibrosis score was significantly lower in cyclosporine-treated patients versus tacrolimus-treated patients (mean 1.7 ± 0.4 vs 3.1 ± 0.4; P = .023), as was percentage of fibrosis grade Ishak ≥4 (7% vs 41%; P = .028). The mean time to moderate fibrosis (Ishak score ≥3) was 38.2 ± 15.1 months in cyclosporine patients (4/15) and 23.5 ± 12.6 months in tacrolimus patients (14/22); the difference was not statistically significant (P = .09). This retrospective study suggests that cyclosporine-based immunosuppression is associated with less severe hepatic fibrosis in HCV-positive liver transplant recipients compared with tacrolimus-based regimens, but a larger prospective comparative trial is necessary to confirm these findings.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2010 by Elsevier Inc. All rights reserved.